Zelensky asks allies to use ‘all means’ to force Russia into peace talks globalnation.inquirer.net
Day: May 27, 2024
Yahoo! Voices
The New York Times
International parties react strongly to Rafah strike The Jerusalem Post
The company behind the weight-loss drug has made millions, but without health insurance it is unaffordable for many. George Chidi reports. Help support our independent journalism at theguardian.com/infocus
The company behind the weight-loss drug has made millions, but without health insurance it is unaffordable for many. George Chidi reports
George Chidi, a politics and democracy reporter for Guardian US, recently came to Europe on holiday. He had been looking forward to eating his way around Paris and London, and was especially looking forward to the cheese. But when he got here, something surprised him. He enjoyed the food but found he wasn’t overeating.
For the past few months, he explains to Hannah Moore, he has been taking the weight-loss drug Ozempic. Almost 2% of the population in the US is taking it and the company behind it is worth billions. But while it’s been a big year for semaglutide weight-loss drugs such as Ozempic, the changes they are making to US society are only just beginning.